Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Quanterix Corporation
Quanterix Corporation News
Quanterix Corporation Quantitative Score
About Quanterix Corporation
Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. It offers HD-X instrument, a sensitive automated multiplex protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection technology in various applications, including direct detection of nucleic acids. The company also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assay kits and other consumables such as reagents. In addition, it offers contract research services, including sample testing, homebrew assay development, and custom development services. The company primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct sales force, support organizations, and distributors or sales agents. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.
Quanterix Corporation Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
Quanterix Corporation Financials
Table Compare
Compare QTRX metrics with: | |||
|---|---|---|---|
Earnings & Growth | QTRX | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | QTRX | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | QTRX | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | QTRX | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Quanterix Corporation Income
Quanterix Corporation Balance Sheet
Quanterix Corporation Cash Flow
Quanterix Corporation Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Strong Buy |
| Return on Equity | Strong Sell |
| Return on Assets | Strong Sell |
| Debt/Equity Ratio | Neutral |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Buy |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Historical Market Cap
Shares Outstanding
Quanterix Corporation Executives
| Name | Role |
|---|---|
| Dr. Masoud Toloue Ph.D. | President, Chief Executive Officer & Director |
| Ms. Vandana Sriram CPA | Chief Financial Officer & Treasurer |
| Dr. Mark T. Roskey Ph.D. | Chief Science & Collaboration Officer |
| Dr. David R. Walt Ph.D. | Co-Founder, Chairman of Scientific Advisory Board & Independent Director |
| Mr. Naren Bhat | Senior Vice President of Corporate Development & Strategy |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Dr. Masoud Toloue Ph.D. | President, Chief Executive Officer & Director | 1981 | 1.23M | |
| Ms. Vandana Sriram CPA | Chief Financial Officer & Treasurer | Female | 1974 | 717.53K |
| Dr. Mark T. Roskey Ph.D. | Chief Science & Collaboration Officer | 1960 | 495.03K | |
| Dr. David R. Walt Ph.D. | Co-Founder, Chairman of Scientific Advisory Board & Independent Director | 1953 | 47.5K | |
| Mr. Naren Bhat | Senior Vice President of Corporate Development & Strategy | Male | -- |
Quanterix Corporation Insider Trades
| Date | 15 Jun |
| Name | Toloue Masoud |
| Role | President & CEO |
| Transaction | Disposed |
| Type | F-InKind |
| Shares | 1242 |
| Date | 15 Jun |
| Name | Sriram Vandana |
| Role | Chief Financial Officer |
| Transaction | Disposed |
| Type | F-InKind |
| Shares | 229 |
| Date | 12 Jun |
| Name | WALT DAVID R |
| Role | Director |
| Transaction | Acquired |
| Type | P-Purchase |
| Shares | 36010 |
| Date | 13 Jun |
| Name | WALT DAVID R |
| Role | Director |
| Transaction | Acquired |
| Type | P-Purchase |
| Shares | 123990 |
| Date | 9 Jun |
| Name | Toloue Masoud |
| Role | President & CEO |
| Transaction | Acquired |
| Type | P-Purchase |
| Shares | 45900 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 15 Jun | Toloue Masoud | President & CEO | Disposed | F-InKind | 1242 |
| 15 Jun | Sriram Vandana | Chief Financial Officer | Disposed | F-InKind | 229 |
| 12 Jun | WALT DAVID R | Director | Acquired | P-Purchase | 36010 |
| 13 Jun | WALT DAVID R | Director | Acquired | P-Purchase | 123990 |
| 9 Jun | Toloue Masoud | President & CEO | Acquired | P-Purchase | 45900 |